Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy Trial met primary endpoint, median 28-day major motor seizure frequency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback